CA2607771A1 - Anticorps recombinant humanise contre le virus de l'encephalite equine du venezuela - Google Patents
Anticorps recombinant humanise contre le virus de l'encephalite equine du venezuela Download PDFInfo
- Publication number
- CA2607771A1 CA2607771A1 CA002607771A CA2607771A CA2607771A1 CA 2607771 A1 CA2607771 A1 CA 2607771A1 CA 002607771 A CA002607771 A CA 002607771A CA 2607771 A CA2607771 A CA 2607771A CA 2607771 A1 CA2607771 A1 CA 2607771A1
- Authority
- CA
- Canada
- Prior art keywords
- rab
- humanized
- seq
- veev
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000700605 Viruses Species 0.000 title description 10
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 title description 4
- 206010014611 Encephalitis venezuelan equine Diseases 0.000 title description 3
- 201000009145 Venezuelan equine encephalitis Diseases 0.000 title description 3
- 241001529936 Murinae Species 0.000 claims abstract description 56
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 16
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract 7
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims description 56
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 25
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 21
- 208000015181 infectious disease Diseases 0.000 claims description 20
- 238000011321 prophylaxis Methods 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 10
- 238000010367 cloning Methods 0.000 claims description 8
- 150000007523 nucleic acids Chemical group 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 101710091045 Envelope protein Proteins 0.000 claims description 3
- 101710188315 Protein X Proteins 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims 6
- 239000013599 cloning vector Substances 0.000 claims 6
- 239000003085 diluting agent Substances 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 6
- 239000013604 expression vector Substances 0.000 claims 6
- 102100021696 Syncytin-1 Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 13
- 239000013598 vector Substances 0.000 abstract description 12
- 108090001126 Furin Proteins 0.000 description 21
- 102000004961 Furin Human genes 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 230000003472 neutralizing effect Effects 0.000 description 12
- 241000282412 Homo Species 0.000 description 10
- 229960005486 vaccine Drugs 0.000 description 10
- 230000027455 binding Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 8
- 238000013459 approach Methods 0.000 description 7
- 210000004602 germ cell Anatomy 0.000 description 7
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 7
- 238000006386 neutralization reaction Methods 0.000 description 7
- 241000283690 Bos taurus Species 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 241000283073 Equus caballus Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 206010014599 encephalitis Diseases 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 102100021966 Coiled-coil domain-containing protein 34 Human genes 0.000 description 4
- 101150008942 J gene Proteins 0.000 description 4
- 101710120037 Toxin CcdB Proteins 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 101150063325 ab gene Proteins 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 102000008482 12E7 Antigen Human genes 0.000 description 2
- 108010020567 12E7 Antigen Proteins 0.000 description 2
- 241000710929 Alphavirus Species 0.000 description 2
- 101710121417 Envelope glycoprotein Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 2
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 101150117115 V gene Proteins 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 102000054751 human RUNX1T1 Human genes 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 101150117081 51 gene Proteins 0.000 description 1
- 101150044182 8 gene Proteins 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 101001052506 Homo sapiens Microtubule-associated proteins 1A/1B light chain 3A Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 101710125507 Integrase/recombinase Proteins 0.000 description 1
- 101150045458 KEX2 gene Proteins 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 102000006437 Proprotein Convertases Human genes 0.000 description 1
- 108010044159 Proprotein Convertases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710132593 Protein E2 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101800001473 Spike glycoprotein E2 Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001130 anti-lysozyme effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 101150046339 fur gene Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 102000049701 human MAP1LC3A Human genes 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000002962 plaque-reduction assay Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 108010018381 streptavidin-binding peptide Proteins 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002607771A CA2607771A1 (fr) | 2007-11-01 | 2007-11-01 | Anticorps recombinant humanise contre le virus de l'encephalite equine du venezuela |
| GB201009145A GB2467491C (en) | 2007-11-01 | 2008-11-03 | Humanized anti-Venezuelan equine encephalitis virus recombinant antibodies |
| CA2704119A CA2704119C (fr) | 2007-11-01 | 2008-11-03 | Anticorps humanises de recombinaison contre le virus de l'encephalite equine du venezuela |
| PCT/CA2008/001940 WO2009055936A1 (fr) | 2007-11-01 | 2008-11-03 | Anticorps humanisés de recombinaison contre le virus de l'encéphalite équine du vénézuéla |
| US12/740,826 US8501157B2 (en) | 2007-11-01 | 2008-11-03 | Humanized anti-Venezuelan equine encephalitis virus recombinant antibodies |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002607771A CA2607771A1 (fr) | 2007-11-01 | 2007-11-01 | Anticorps recombinant humanise contre le virus de l'encephalite equine du venezuela |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2607771A1 true CA2607771A1 (fr) | 2009-05-01 |
Family
ID=40589892
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002607771A Abandoned CA2607771A1 (fr) | 2007-11-01 | 2007-11-01 | Anticorps recombinant humanise contre le virus de l'encephalite equine du venezuela |
| CA2704119A Expired - Fee Related CA2704119C (fr) | 2007-11-01 | 2008-11-03 | Anticorps humanises de recombinaison contre le virus de l'encephalite equine du venezuela |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2704119A Expired - Fee Related CA2704119C (fr) | 2007-11-01 | 2008-11-03 | Anticorps humanises de recombinaison contre le virus de l'encephalite equine du venezuela |
Country Status (3)
| Country | Link |
|---|---|
| CA (2) | CA2607771A1 (fr) |
| GB (1) | GB2467491C (fr) |
| WO (1) | WO2009055936A1 (fr) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8501157B2 (en) | 2007-11-01 | 2013-08-06 | Her Majesty the Queen in right of Canada as represented by The Ministry of National Defence | Humanized anti-Venezuelan equine encephalitis virus recombinant antibodies |
| EP3315606A4 (fr) * | 2015-06-24 | 2019-04-24 | JCR Pharmaceuticals Co., Ltd. | Anticorps anti-récepteur de transferrine humaine passant au travers de la barrière hématoencéphalique |
| US10759864B2 (en) | 2016-12-26 | 2020-09-01 | Jcr Pharmaceuticals Co., Ltd. | Anti-human transferrin receptor antibody capable of penetrating blood-brain barrier |
| US11130815B2 (en) | 2015-06-24 | 2021-09-28 | Jcr Pharmaceuticals Co., Ltd. | Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0916630D0 (en) * | 2009-09-22 | 2009-11-04 | Secr Defence | Antibody |
| EA030436B1 (ru) | 2010-11-04 | 2018-08-31 | Бёрингер Ингельхайм Интернациональ Гмбх | АНТИТЕЛА К IL-23p19 ИЛИ ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ФРАГМЕНТЫ, ИХ ПРИМЕНЕНИЕ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ЭТИ АНТИТЕЛА, СПОСОБ ИХ ПОЛУЧЕНИЯ, ВЫДЕЛЕННЫЕ ПОЛИНУКЛЕОТИДЫ, ЭКСПРЕССИОННЫЕ ВЕКТОРЫ И КЛЕТКИ ДЛЯ ПОЛУЧЕНИЯ АНТИТЕЛ |
| CN109206516A (zh) | 2012-05-03 | 2019-01-15 | 勃林格殷格翰国际有限公司 | 抗IL-23p19抗体 |
| EP3708679A1 (fr) | 2014-07-24 | 2020-09-16 | Boehringer Ingelheim International GmbH | Biomarqueurs utiles dans le traitement de maladies liées à l'il-23a |
| AR101753A1 (es) | 2014-09-03 | 2017-01-11 | Boehringer Ingelheim Int | COMPUESTO DE OBJETIVO A IL-23A Y TNF-a Y USO DEL MISMO |
| CN107586335B (zh) * | 2016-07-06 | 2020-12-29 | 中国科学院微生物研究所 | 一种人源化单克隆抗体及应用 |
-
2007
- 2007-11-01 CA CA002607771A patent/CA2607771A1/fr not_active Abandoned
-
2008
- 2008-11-03 WO PCT/CA2008/001940 patent/WO2009055936A1/fr active Application Filing
- 2008-11-03 CA CA2704119A patent/CA2704119C/fr not_active Expired - Fee Related
- 2008-11-03 GB GB201009145A patent/GB2467491C/en not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8501157B2 (en) | 2007-11-01 | 2013-08-06 | Her Majesty the Queen in right of Canada as represented by The Ministry of National Defence | Humanized anti-Venezuelan equine encephalitis virus recombinant antibodies |
| EP3315606A4 (fr) * | 2015-06-24 | 2019-04-24 | JCR Pharmaceuticals Co., Ltd. | Anticorps anti-récepteur de transferrine humaine passant au travers de la barrière hématoencéphalique |
| US11130815B2 (en) | 2015-06-24 | 2021-09-28 | Jcr Pharmaceuticals Co., Ltd. | Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody |
| US11248045B2 (en) | 2015-06-24 | 2022-02-15 | Jcr Pharmaceuticals Co., Ltd. | Anti-human transferrin receptor antibody permeating blood-brain barrier |
| US11958905B2 (en) | 2015-06-24 | 2024-04-16 | Jcr Pharmaceuticals Co., Ltd. | Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody |
| US10759864B2 (en) | 2016-12-26 | 2020-09-01 | Jcr Pharmaceuticals Co., Ltd. | Anti-human transferrin receptor antibody capable of penetrating blood-brain barrier |
| US11111308B2 (en) | 2016-12-26 | 2021-09-07 | Jcr Pharmaceuticals Co., Ltd. | Anti-human transferrin receptor antibody capable of penetrating blood-brain barrier |
Also Published As
| Publication number | Publication date |
|---|---|
| GB201009145D0 (en) | 2010-07-14 |
| GB2467491C (en) | 2013-03-27 |
| CA2704119A1 (fr) | 2009-05-07 |
| GB2467491A (en) | 2010-08-04 |
| GB2467491B (en) | 2013-03-20 |
| GB2467491A8 (en) | 2010-12-22 |
| WO2009055936A1 (fr) | 2009-05-07 |
| CA2704119C (fr) | 2014-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090117105A1 (en) | Humanized anti-venezuelan equine encephalitis virus recombinant antibody | |
| CA2704119C (fr) | Anticorps humanises de recombinaison contre le virus de l'encephalite equine du venezuela | |
| JP5346820B2 (ja) | Ｈ５ｎ１亜型ａ型インフルエンザウィルスに対する抗体 | |
| EP3572125A2 (fr) | Anticorps monoclonaux contre les virus d'ebola et de marburg | |
| CN110317267B (zh) | 针对狂犬病病毒的双特异性抗体及其用途 | |
| AU2005214988A1 (en) | Super-humanized antibodies against respiratory syncytial virus | |
| US20170065702A1 (en) | Methods of modulating an immune response | |
| US20170158753A1 (en) | Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species | |
| US20180237502A1 (en) | Pan-ebola and pan-filovirus protective epitopes, antibodies, and antibody cocktails | |
| Unkauf et al. | Generation of recombinant antibodies against toxins and viruses by phage display for diagnostics and therapy | |
| Hu et al. | Humanization and mammalian expression of a murine monoclonal antibody against Venezuelan equine encephalitis virus | |
| CN115515976A (zh) | 冠状病毒抗体 | |
| DK3150632T3 (en) | ANTI-RICIN ANTIBODIES AND APPLICATIONS THEREOF | |
| EP4353744A1 (fr) | Anticorps contre le virus respiratoire syncytial et son utilisation | |
| US11440951B2 (en) | Therapeutic antibodies to Marburg virus | |
| US8501157B2 (en) | Humanized anti-Venezuelan equine encephalitis virus recombinant antibodies | |
| Lamarre et al. | A recombinant single chain antibody neutralizes coronavirus infectivity but only slightly delays lethal infection of mice | |
| EP3525813B1 (fr) | Anticorps neutralisant à large spectre ciblant la boucle de fusion interne de la glycoprotéine du virus ebola | |
| US7622111B2 (en) | Fusion protein of human IgG1 heavy chain constant region and scFv antibody against equine encephalitis virus | |
| WO2020146421A1 (fr) | Anticorps monoclonaux ciblant gp38 protégeant des souris adultes contre une infection par le virus de la fièvre hémorragique de crimée-congo létale | |
| CN111032077A (zh) | 抗-登革热病毒抗体、包含该抗体的药学组合物及其用途 | |
| Frenzel et al. | Characterization of an In Vivo Neutralizing Anti-Vaccinia Virus D8 Single-Chain Fragment Variable (scFv) from a Human Anti-Vaccinia Virus-Specific Recombinant Library | |
| KR20240001181A (ko) | Covid-19 및 신종 변이의 치료 및 예방을 위한 항체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |
Effective date: 20150617 |